Evidence map›Paper›PMID 39862108›Full record

Trial reportClinical trials (London, England)2025

NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants.

Charles Swanton, Velicia Bachtiar, Chris Mathews, Adam R Brentnall, Ian Lowenhoff, Jo Waller, Martine Bomb, Sean McPhail, Heather Pinches, Rebecca Smittenaar and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical trials (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05611632 (A Randomized, Controlled Trial to Assess the Clinical Utility of a Multi-cancer Early Detection), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05611632 naactive not recruitingnot on this map

A Randomized, Controlled Trial to Assess the Clinical Utility of a Multi-cancer Early Detection (MCED) Test for Population Screening in the United Kingdom (UK) When Added to Standard of Care

TypeinterventionalSponsorGRAIL, Inc.Ran2021 to 2031Enrolled142,318ConditionsCancerArmsMulti-cancer early detection test (Galleri test)
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Charles SwantonUniversity College London, London, UK.
Velicia BachtiarGRAIL Bio UK Ltd., GRAIL, Inc., London, UK.
Chris MathewsKing's College London, London, UK.
Adam R BrentnallQueen Mary University of London, London, UK.ORCID 0000-0001-6327-4357
Ian LowenhoffKing's College London, London, UK.
Jo WallerKing's College London, London, UK.
Martine BombNHS England, London, UK.
Sean McPhailNHS England, London, UK.
Heather PinchesNHS England, London, UK.
Rebecca SmittenaarGRAIL Bio UK Ltd., GRAIL, Inc., London, UK.
Sara HiomGRAIL Bio UK Ltd., GRAIL, Inc., London, UK.
Richard D NealUniversity College London, London, UK.
Peter SasieniKing's College London, London, UK.ORCID 0000-0003-1509-8744

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsCertain sociodemographic groups are routinely underrepresented in clinical trials, limiting generalisability. Here, we describe the extent to which enriched enrolment approaches yielded a diverse trial population enriched for older age in a randomised controlled trial of a blood-based multi-cancer early detection test (NCT05611632).

methodsParticipants aged 50-77 years were recruited from eight Cancer Alliance regions in England. Most were identified and invited from centralised health service lists; a dynamic invitation algorithm was used to target those in older and more deprived groups. Others were invited by their general practice surgery (GP-based Participant Identification Centres in selected regions); towards the end of recruitment, specifically Asian and Black individuals were invited via this route, as part of a concerted effort to encourage enrolment among these individuals. Some participants self-referred, often following engagement activities involving community organisations. Enrolment took place in 11 mobile clinics at 151 locations that were generally more socioeconomically deprived and ethnically diverse than the England average. We reduced logistical barriers to trial participation by offering language interpretation and translation and disabled access measures. After enrolment, we examined (1) sociodemographic distribution of participants versus England and Cancer Alliance populations, and (2) number needed to invite (NNI; the number of invitations sent to enrol one participant) by age, sex, index of multiple deprivation (IMD) and ethnicity, and GP surgery-level bowel screening participation.

resultsApproximately 1.5 million individuals were invited and 142,924 enrolled (98% via centralised health service lists/invitation algorithm) in 10.5 months. The enrolled population was older and more deprived than the England population aged 50-77 years (73.3% vs 56.8% aged 60-77 years; 42.3% vs 35.3% in IMD groups 1-2). Ethnic diversity was lower in the trial than the England population (1.4% vs 2.8% Black; 3.3% vs 5.3% Asian). NNI was highest in Black (32.8), Asian (28.2) and most-deprived (21.5) groups, and lowest in mixed ethnicity (8.1) and least-deprived (4.6) groups.

conclusionsEnrolment approaches used in the NHS-Galleri trial enabled recruitment of an older, socioeconomically diverse participant population relatively rapidly. Compared with the England and Cancer Alliance populations, the enrolled population was enriched for those in older age and more deprived groups. Better ethnicity data availability in central health service records could enable better invitation targeting to further enhance ethnically diverse recruitment. Future research should evaluate approaches used to facilitate recruitment from underrepresented groups in clinical trials.

Indexed as

Early Detection of CancerPatient SelectionRandomized Controlled Trials as TopicAgedEnglandFemaleHumansMaleMiddle AgedSociodemographic FactorsSocioeconomic Factorscancercell-free nucleic acidsclinical trial recruitmentequityethnicityliquid biopsyMulti-cancer early detectionpopulation screeningrandomised controlled trialsocioeconomic status

Identifiers

PMID39862108
PMCPMC11986080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.